MRSA is the most common causative pathogen of hospital-treated acute bacterial skin and skin-structure infections (ABSSSI).

It is estimated that MRSA kills more people each year than AIDS/HIV today or the polio epidemic at its peak.

Sources: Zervos MJ et al, Epidemiology and outcomes of complicated skin and soft tissue infections in hospitalized patients. J Clin Microbiol 2012 Feb;50(2):238-45. Doi:10.1128/JCM.05817-11. Epub 2011 Nov 23

Acute bacterial skin and skin structure infections are major reasons for hospitalizations in the United States, affecting millions of people annually

Zervos MJ et al, Epidemiology and Outcomes of Complicated Skin and Soft Tissue Infections in Hospitalized Patients. J Clin Microbiol 2012 Feb;50(2):238-45.

Agency for Healthcare Research and Quality, 2011 data (
At least 2 million people in the U.S. acquire serious infections with bacteria that are resistant to one or more of the antibiotics designed to combat them.

More than 23,000 people in the U.S. die each year from antibiotic-resistant infections. Many more die from conditions complicated by an antibiotic-resistant infection.

Source: U.S. Centers for Disease Control and Prevention (CDC). Antibiotic Resistance Threats in the United States, 2013.

Bassetti, M. et al; DELAFLOXACIN FOR THE TREATMENT OF RESPIRATORY AND SKIN INFECTIONS Expert Opinion on Investigational Drugs, Mar 2015, Vol. 24, No. 3: 433–442.

Published March 2015
Click Here to Read Online15

ESKAPE pathogens are the six resistant bacteria that are among the most difficult to treat:

66% of all hospital infections are caused by ESKAPE pathogens.

Source: Rice LB. Federal Funding for the Study of Antimicrobial Resistance in Nosocomial Pathogens: no ESKAPE. J. Infect. Dis.197(8), 1079-1081 (2008)
Press Releases and News
January 6, 2016
Melinta Therapeutics Initiates Phase 3 Study of Baxdela in Hospital-Treated Community-Acquired Bacterial Pneumonia
January 5, 2016
Melinta Therapeutics to Present at 34th Annual J.P. Morgan Healthcare Conference
October 9, 2015
Melinta Therapeutics Presents Complete Delafloxacin Results from Phase 3 Study in Patients with Acute Bacterial Skin and Skin Structure Infections at ID Week